TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17301564

Group type: EXPERIMENTAL
Intervention: Intermittent antiretroviral therapy (8-week off, 8-week on regimen)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Continuous antiretroviral therapy
Number of subjects: 403

Group type: EXPERIMENTAL
Intervention: Intermittent antiretroviral therapy
Number of subjects: 403
Study: 15064315

Group type: EXPERIMENTAL
Intervention: SCOT I procedure
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: SCOT II procedure
Number of subjects: 54

Group type: COMPARATOR
Intervention: Bilateral total orchiectomy (BTO)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: LHRH agonist
Number of subjects: 54
Study: 11586115

Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Entacapone
Number of subjects: 25
Study: 9505001

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 7635414

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ligation
Number of subjects: 120
Study: 2676558

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 319117

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (120 mg daily for six weeks)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Ibuprofen (2400 mg daily for six weeks)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 208
Study: 31515173

Group type: EXPERIMENTAL
Intervention: Patches plus nicotine e‐cigarette
Number of subjects: 1124

Group type: EXPERIMENTAL
Intervention: Patches plus nicotine‐free e‐cigarette
Number of subjects: 1124

Group type: COMPARATOR
Intervention: Patches only
Number of subjects: 1124
Study: 31183861

Group type: EXPERIMENTAL
Intervention: Modified Mallampati classification
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: First formant of /i/ (iF1)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Second formant of /i/ (iF2)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Regression model including both formants and Mallampati
Number of subjects: 453

Group type: COMPARATOR
Intervention: Formants alone
Number of subjects: 453

Group type: COMPARATOR
Intervention: Modified Mallampati alone
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Voice sounds
Number of subjects: 453
Study: 28103052

Group type: EXPERIMENTAL
Intervention: Micronutrients + medication
Number of subjects: 59

Group type: COMPARATOR
Intervention: Medication only (Control)
Number of subjects: 59
Study: 25760127

Group type: EXPERIMENTAL
Intervention: Traditional motivational strategy + activation of intention strategy (Intervention Group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional motivational strategy (Control Group)
Number of subjects: 0
Study: 23574727

Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Number of subjects: 15

Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 15
Study: 21332679

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with intrathecal morphine
Number of subjects: 162

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 162
Study: 19845035

Group type: EXPERIMENTAL
Intervention: Nabilone (1 or 2 mg)
Number of subjects: 44
Study: 16706691

Group type: EXPERIMENTAL
Intervention: Transcutaneous irradiation with polychromatic visible and infrared light (480-3400 nm, 95% polarization, 12 J/cm²)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transcutaneous irradiation with polychromatic visible and infrared light
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro irradiation of blood (2.4 J/cm²)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixing irradiated and non-irradiated autologous blood at a volume ratio 1:10
Number of subjects: 0
Study: 14995150

Group type: EXPERIMENTAL
Intervention: Chromium supplementation (1000 microg/day as Cr yeast)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11405578

Group type: EXPERIMENTAL
Intervention: Presence of referential cues in emotional messages
Number of subjects: 80

Group type: COMPARATOR
Intervention: Absence of referential cues in emotional messages
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Consultation of referential cues to disambiguate emotional displays
Number of subjects: 80
Study: 9163639

Group type: EXPERIMENTAL
Intervention: CDP840 (15 mg b.i.d. for 9.5 days)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CDP840 (15 and 30 mg single dose)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 8354046

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 6384558

Group type: EXPERIMENTAL
Intervention: PGE1 (20 ng/kg/min) for 72 hours
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30390148

Group type: EXPERIMENTAL
Intervention: Feedback Informed Treatment (FIT)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 166
Study: 29880245

Group type: EXPERIMENTAL
Intervention: HPV vaccination program
Number of subjects: 142
Study: 26859481

Group type: EXPERIMENTAL
Intervention: Ready-to-use therapeutic food (RUTF) - 1 sachet/day for 14 days
Number of subjects: 2202

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (MNP) - 2 sachets/day for 14 days
Number of subjects: 2202

Group type: COMPARATOR
Intervention: Control - no supplement
Number of subjects: 2202
Study: 25410633

Group type: EXPERIMENTAL
Intervention: Psychological online intervention (Deprexis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control (WLC)
Number of subjects: 0
Study: 22155477

Group type: EXPERIMENTAL
Intervention: Dopaminergic medication ON
Number of subjects: 0

Group type: COMPARATOR
Intervention: No dopaminergic medication OFF
Number of subjects: 0
Study: 20460027

Group type: EXPERIMENTAL
Intervention: Wound infiltration with local anaesthetic after CS under regional analgesia
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Wound infiltration and peritoneal spraying with local anaesthetic after CS under general anaesthesia
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Local anaesthetic and non-steroidal anti-inflammatory cocktail wound infiltration after CS under regional analgesia
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Abdominal nerve blocks after regional analgesia
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Wound infiltration with a mixture of local analgesia and narcotics
Number of subjects: 1150
Study: 17215845

Group type: EXPERIMENTAL
Intervention: Grapefruit juice consumption (concomitantly or 2 hours before fexofenadine administration)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fexofenadine
Number of subjects: 0
Study: 16713831

Group type: EXPERIMENTAL
Intervention: Percutaneous needle fasciotomy (PNF)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Limited fasciectomy (LF)
Number of subjects: 166
Study: 15164249

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate with E-Lyte supplements (Group 1)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Oral sodium phosphate without E-Lyte supplements (Group 2)
Number of subjects: 187
Study: 10731002

Group type: EXPERIMENTAL
Intervention: 1-arm cranking
Number of subjects: 7

Group type: COMPARATOR
Intervention: 2-leg cycling
Number of subjects: 7
Study: 8777618

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (1.2 g daily, divided into three doses for 2 months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 36
Study: 1801880

Group type: EXPERIMENTAL
Intervention: BFM Protocol ALL-BFM 81
Number of subjects: 897

Group type: COMPARATOR
Intervention: DFCI Protocol DFCI 81-01
Number of subjects: 897
Study: 6596060

Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intravenous streptokinase therapy (1 million IU over 20 minutes)
Number of subjects: 20
Study: 30711868

Group type: EXPERIMENTAL
Intervention: Group Laughter Yoga intervention (n = 23), consisting of eight sessions over four weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment-as-usual (n = 27)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Group Laughter Yoga intervention (n = 23)
Number of subjects: 50
Study: 29479906

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment in patients with exudative ARMD and POAG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Bevacizumab treatment in patients with DME and POAG
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (fellow eye not treated with bevacizumab)
Number of subjects: 60
Study: 25562457

Group type: EXPERIMENTAL
Intervention: 4‐week balance‐training program
Number of subjects: 31

Group type: COMPARATOR
Intervention: No balance training (control group)
Number of subjects: 31
Study: 23452665

Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Social skills training (active control)
Number of subjects: 30
Study: 21387137

Group type: EXPERIMENTAL
Intervention: High-pressure pulsatile lavage
Number of subjects: 79

Group type: COMPARATOR
Intervention: Low-pressure pulsatile lavage
Number of subjects: 79
Study: 19258303

Group type: EXPERIMENTAL
Intervention: Motivational orientation intervention combined with Parent-Child Interaction Therapy (PCIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard orientation
Number of subjects: 0
Study: 17133139

Group type: EXPERIMENTAL
Intervention: Fluorocarbon polymer film applied to adhesive surface of skin barrier
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional stainless steel plate-based testing method
Number of subjects: 12
Study: 15319158

Group type: EXPERIMENTAL
Intervention: Finasteride 1 mg
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Finasteride 0.2 mg
Number of subjects: 414

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 414
Study: 11087700

Group type: EXPERIMENTAL
Intervention: Combined treatment (high response)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Sulfasalazine treatment (moderate response)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Patient's assessment of change in disease activity
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Core set measures
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: EULAR response criteria
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: ACR improvement criteria
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Health Assessment Questionnaire (HAQ)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Grip strength
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Patient utility (generic health status measure)
Number of subjects: 155
Study: 9305476

Group type: EXPERIMENTAL
Intervention: Enema (100 mL suspension, 1 g mesalazine)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Rectal foam (1 g mesalazine in 5 mL concentrate, expanding to 40 mL on actuation)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Suppository (1 g mesalazine)
Number of subjects: 8
Study: 8437356

Group type: EXPERIMENTAL
Intervention: Group 2 (ETT hooked on the distal end of the stylet at the Murphy eye)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Group 3 (ETT rotated 180 degrees so that the bevel was directed to the right)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Group 1 (control, ETT attached naturally to the stylet with the bevel facing left)
Number of subjects: 108
Study: 3512970

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cisdiamminedichloro-platinum plus methotrexate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 0
Study: 31023842

Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 184
Study: 28452570

Group type: EXPERIMENTAL
Intervention: Screening tool (Surprise Question plus Supportive and Palliative Care Indicators Tool)
Number of subjects: 4365

Group type: COMPARATOR
Intervention: Unguided intuition
Number of subjects: 4365
Study: 27511847

Group type: EXPERIMENTAL
Intervention: TARGIT‐IORT (single-dose intraoperative radiation therapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EBRT (external beam radiation therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both TARGIT‐IORT and EBRT
Number of subjects: 0
Study: 24418248

Group type: EXPERIMENTAL
Intervention: Soy protein/isoflavone-based meal replacement
Number of subjects: 120

Group type: COMPARATOR
Intervention: Casein-based meal replacement
Number of subjects: 120
Study: 23284643

Group type: EXPERIMENTAL
Intervention: Umeclidinium (500 µg) and vilanterol (50 µg) combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Umeclidinium (500 µg) alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vilanterol (50 µg) alone
Number of subjects: 0
Study: 20192619

Group type: EXPERIMENTAL
Intervention: 20% lignocaine patch
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 5% EMLA
Number of subjects: 25

Group type: COMPARATOR
Intervention: Electronic dental anesthesia (EDA)
Number of subjects: 25
Study: 18184544

Group type: EXPERIMENTAL
Intervention: Sijunzi Decoction (100 ml) administered via nasogastric tube from the second postoperation day to the 9th postoperation day, along with isocaloric and isonitrogonous enteral diet for 8 days
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Isocaloric and isonitrogonous enteral diet started on the second day after operation for 8 days
Number of subjects: 59

Group type: COMPARATOR
Intervention: Isocaloric and isonitrogonous parenteral diet for 9 days
Number of subjects: 59
Study: 15568191

Group type: EXPERIMENTAL
Intervention: Enhanced gatekeeping procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parallel gatekeeping procedure
Number of subjects: 0
Study: 11547064

Group type: EXPERIMENTAL
Intervention: Selenium and Vitamin E
Number of subjects: 32400

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32400
Study: 9686462

Group type: EXPERIMENTAL
Intervention: Concern-related suggestions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Other topic suggestions
Number of subjects: 10
Study: 8136110

Group type: EXPERIMENTAL
Intervention: Quinapril (mean dose 32 mg/24 h)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Captopril (mean dose 132 mg/24 h)
Number of subjects: 36
Study: 2644532

Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice a day)
Number of subjects: 2644

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2644
Study: 1201165

Group type: EXPERIMENTAL
Intervention: Enflurane
Number of subjects: 104

Group type: COMPARATOR
Intervention: Halothane
Number of subjects: 104
Study: 31732522

Group type: COMPARATOR
Intervention: Gene signature (GS) in melanoma training set
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gene signature (GS) in melanoma test set
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multivariate Cox model in melanoma test set
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Th1/IFNγ-related genes in NSCLC
Number of subjects: 0
Study: 31585686

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study: 27768831

Group type: EXPERIMENTAL
Intervention: Denosumab (60 mg subcutaneous once)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Alendronate (70 mg oral weekly for 6 months)
Number of subjects: 40
Study: 25936227

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Venlafaxine-XR
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 1008
Study: 23850898

Group type: EXPERIMENTAL
Intervention: 200 μg misoprostol vaginally at 6 hours before outpatient hysteroscopy and placebo tablets rectally at 60 minutes before the procedure.
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 100 mg diclofenac sodium rectally at 60 minutes before the procedure and placebo tablets rectally at 6 hours before outpatient hysteroscopy.
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo tablets vaginally at 6 hours before outpatient hysteroscopy and placebo tablets rectally at 45 to 60 minutes before the procedure.
Number of subjects: 158
Study: 21788632

Group type: EXPERIMENTAL
Intervention: Maximal treatment group (mobile and web-based self-management patient coaching system)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Maximal treatment group
Number of subjects: 163

Group type: COMPARATOR
Intervention: Maximal treatment group and Usual care
Number of subjects: 163
Study: 18586757

Group type: EXPERIMENTAL
Intervention: Face-to-face intervention (brief dialogue with patients)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Video watching (overview of peripheral arterial disease)
Number of subjects: 51
Study: 17013438

Group type: EXPERIMENTAL
Intervention: 6-methylprednisolone (20 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients with SLE or UCTD
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Patients with UCTD
Number of subjects: 23

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 23
Study: 15287932

Group type: COMPARATOR
Intervention: Acarbose 100 mg (one-dose)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acarbose 300 mg/day for 8 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acarbose (one-dose)
Number of subjects: 80
Study: 10924631

Group type: EXPERIMENTAL
Intervention: Laparoscopy with mechanical elevation of the abdominal wall (MEA)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Laparoscopy with CO2 insufflation (CI)
Number of subjects: 31
Study: 8612858

Group type: EXPERIMENTAL
Intervention: Intranasal buserelin acetate started in the midluteal phase
Number of subjects: 124

Group type: COMPARATOR
Intervention: Intranasal buserelin acetate started in the early follicular phase
Number of subjects: 124
Study: 1611136

Group type: EXPERIMENTAL
Intervention: ponalrestat (600 mg daily)
Number of subjects: 259

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 259
Study: 6360414

Group type: EXPERIMENTAL
Intervention: Cholestyramine (6 g four times daily)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 31962305

Group type: EXPERIMENTAL
Intervention: 100 Hz local vibration for 10 minutes
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 35 Hz local vibration for 10 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0 Hz (sham control) local vibration for 10 minutes
Number of subjects: 12
Study: 29751347

Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice per day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 28628768

Group type: EXPERIMENTAL
Intervention: Internet delivered Cognitive Behavior Therapy (ICBT) as an add‐on to usual care
Number of subjects: 42

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) provided at their antenatal clinic
Number of subjects: 42
Study: 25740744

Group type: EXPERIMENTAL
Intervention: DAG oil (25 mL/d for 120 days)
Number of subjects: 127

Group type: COMPARATOR
Intervention: TAG oil (25 mL/d for 120 days)
Number of subjects: 127
Study: 23465817

Group type: EXPERIMENTAL
Intervention: Progesterone vaginal ring (VR)
Number of subjects: 1297

Group type: COMPARATOR
Intervention: Progesterone vaginal gel (VG)
Number of subjects: 1297
Study: 21925737

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Contact lens
Number of subjects: 114
Study: 18663631

Group type: EXPERIMENTAL
Intervention: Estrogen and estrogen/progestin hormone therapies (HT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Timing hypothesis for hormone therapy
Number of subjects: 0
Study: 16807272

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation
Number of subjects: 81

Group type: COMPARATOR
Intervention: Hospital-based cardiac rehabilitation
Number of subjects: 81
Study: 14689344

Group type: EXPERIMENTAL
Intervention: Mupirocin therapy
Number of subjects: 2445

Group type: COMPARATOR
Intervention: Placebo or no therapy
Number of subjects: 2445
Study: 10340921

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8890965

Group type: EXPERIMENTAL
Intervention: Theoretical and practical session for breast self-examination
Number of subjects: 657

Group type: COMPARATOR
Intervention: Mailed material for breast self-examination
Number of subjects: 657
Study: 1793154

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide (CPM) and high-dose methotrexate (MTX) with coordinated intrathecal therapy (TIT)
Number of subjects: 117

Group type: COMPARATOR
Intervention: 2 cycles of vincristine plus MTX with leucovorin rescue
Number of subjects: 117

Group type: COMPARATOR
Intervention: 6 cycles of vincristine plus MTX with leucovorin rescue
Number of subjects: 117
Study: 6337365

Group type: EXPERIMENTAL
Intervention: Cyclacillin, administered three times a day for ten days
Number of subjects: 240

Group type: COMPARATOR
Intervention: Amoxicillin, administered similarly
Number of subjects: 240
Study: 2413646

Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 161

Group type: COMPARATOR
Intervention: Control
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 161
Study: 29024579

Group type: EXPERIMENTAL
Intervention: Droxidopa 600 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Droxidopa 2000 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27092710

Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 322
Study: 24257892

Group type: EXPERIMENTAL
Intervention: SLT 2 in the same TM area
Number of subjects: 40

Group type: COMPARATOR
Intervention: SLT 2 in the upper untreated TM area
Number of subjects: 40
Study: 24088091

Group type: EXPERIMENTAL
Intervention: Planned cesarean delivery
Number of subjects: 2795

Group type: COMPARATOR
Intervention: Planned vaginal delivery
Number of subjects: 2795
Study: 20431391

Group type: EXPERIMENTAL
Intervention: Dietary pattern positively correlated with meat and alcohol consumption and negatively correlated with fibers, vitamins B9 and C, β-carotene and calcium consumption.
Number of subjects: 1026

Group type: EXPERIMENTAL
Intervention: Other dietary patterns (not specified)
Number of subjects: 1026